Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Docetaxel is active in paclitaxel-resistant ovarian and peritoneal cancer, but, in view of significant hematologic toxicity, further study is warranted to ascertain its optimal dose and schedule.

A Phase II Study of Docetaxel in Paclitaxel-Resistant Ovarian and Peritoneal Carcinoma